FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108479875> ?p ?o ?g. }

• W2108479875 endingPage "2120" @default.
• W2108479875 startingPage "2119" @default.
• W2108479875 abstract "There is increasing interest in the potential role of antithrombotic agents in the management of cancer patients. Low molecular weight heparins (LMWHs) have generated particular excitement because they have been validated in both the prevention and the treatment of thromboembolic disease in patients with malignancy. Retrospective analyses of clinical trials in which LMWH had been used to treat established thrombosis in cancer patients have suggested a survival advantage for the treated groups. The studies that formed the basis of these meta-analyses were not primarily designed to assess cancer outcomes, and little was known about the distribution of prognostic variables between groups of patients treated with different antithrombotic therapies in these trials. Thus, clear conclusions about the potential benefits of LMWH and long-term survival could not be established. Earlier this year, the first prospective, randomized, double-blind study designed to assess the potential value of long-term LMWH therapy to improve survival in cancer patients was reported. The study failed to achieve the predefined difference in mortality between groups of patients randomly assigned to placebo or LMWH, but did suggest a striking survival advantage for heparin treatment in a subgroup of patients with good-prognosis tumors. More recently, a second clinical trial in patients with small-cell lung carcinoma—again with random assignment to standard care with combination chemotherapy alone compared with LMWH plus standard care—showed advantages in terms of progression-free and overall survival for patients who received LMWH for 18 weeks. In this issue of the Journal of Clinical Oncology, two additional studies report on the potential benefits of longer term LMWH therapy for cancer patients. The first, by Lee et al, is the long-term follow-up patients in the Comparison of Low Molecular Weight Heparin Versus Oral Anticoagulant Therapy for Long Term Anticoagulation in Cancer Patients With Venous Thromboembolism (CLOT) trial. This study randomly assigned 676 patients to oral anticoagulant therapy or LMWH therapy for 6 months for treatment of acute, symptomatic, proximal vein thrombosis. The primary end point of the study was to determine rates of recurrent thromboembolic disease, but included a secondary end point of survival at 1 year. This trial showed that there is a survival benefit with LMWH therapy in the subgroup of patients without evident metastatic disease at the time of random assignment to treatment. A second study, by Klerk et al, showed the value of up to 6 weeks of LMWH therapy compared with placebo in patients with advanced malignant disease. A variety of tumor types were included in this study and for both the overall trial population and for a subgroup of patients with better prognosis at the time of random assignment, LMWH therapy was associated with a significant survival advantage. How might these interesting observations be explained? It could be that the administration of antithrombotic therapy to patients in these trials reduced the frequency of fatal pulmonary embolism. However, in the study by Klerk et al, the benefits of LMWH therapy were seen for months and years after the period of active administration (indeed, there was no obvious survival advantage in the acute treatment period), suggesting the mechanism is not purely an antithrombotic effect. This feature was also seen in other studies in which LMWH therapy was given to patients without underlying thromboembolic disease. It is more likely that the mechanism of this long-term benefit can be explained through effects on tumor cell biology. In this regard, there has been extensive evaluation of the potential role that the coagulation proteases play in tumorstromal interactions at a molecular level. Tissue factor (TF) is frequently overexpressed as a result of progression from benign to malignant phenotype, and that overexpression is associated with aggressive behavior and poor outcome in pancreatic cancer, among other tumors. TF, the physiological initiator of blood coagulation, is also known to have a strong structural homology with the class II cytokine receptor family. Identification of filamin A, as an JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 23 NUMBER 10 APRIL 1 2005" @default.
• W2108479875 created "2016-06-24" @default.
• W2108479875 creator A5025477800 @default.
• W2108479875 date "2005-04-01" @default.
• W2108479875 modified "2023-10-05" @default.
• W2108479875 title "Antithrombotic Therapy in Cancer" @default.
• W2108479875 cites W145628542 @default.
• W2108479875 cites W1862276591 @default.
• W2108479875 cites W1987573231 @default.
• W2108479875 cites W2002728088 @default.
• W2108479875 cites W2003046222 @default.
• W2108479875 cites W2013984355 @default.
• W2108479875 cites W2028222320 @default.
• W2108479875 cites W2037490988 @default.
• W2108479875 cites W2041709488 @default.
• W2108479875 cites W2101137688 @default.
• W2108479875 cites W2141269861 @default.
• W2108479875 cites W2142386661 @default.
• W2108479875 cites W2146508957 @default.
• W2108479875 cites W2150238019 @default.
• W2108479875 cites W2159985197 @default.
• W2108479875 doi "https://doi.org/10.1200/jco.2005.10.975" @default.
• W2108479875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15699474" @default.
• W2108479875 hasPublicationYear "2005" @default.
• W2108479875 type Work @default.
• W2108479875 sameAs 2108479875 @default.
• W2108479875 citedByCount "18" @default.
• W2108479875 countsByYear W21084798752012 @default.
• W2108479875 countsByYear W21084798752013 @default.
• W2108479875 countsByYear W21084798752014 @default.
• W2108479875 countsByYear W21084798752017 @default.
• W2108479875 crossrefType "journal-article" @default.
• W2108479875 hasAuthorship W2108479875A5025477800 @default.
• W2108479875 hasBestOaLocation W21084798751 @default.
• W2108479875 hasConcept C121608353 @default.
• W2108479875 hasConcept C126322002 @default.
• W2108479875 hasConcept C143998085 @default.
• W2108479875 hasConcept C2777015399 @default.
• W2108479875 hasConcept C71924100 @default.
• W2108479875 hasConceptScore W2108479875C121608353 @default.
• W2108479875 hasConceptScore W2108479875C126322002 @default.
• W2108479875 hasConceptScore W2108479875C143998085 @default.
• W2108479875 hasConceptScore W2108479875C2777015399 @default.
• W2108479875 hasConceptScore W2108479875C71924100 @default.
• W2108479875 hasIssue "10" @default.
• W2108479875 hasLocation W21084798751 @default.
• W2108479875 hasLocation W21084798752 @default.
• W2108479875 hasOpenAccess W2108479875 @default.
• W2108479875 hasPrimaryLocation W21084798751 @default.
• W2108479875 hasRelatedWork W2546345250 @default.
• W2108479875 hasRelatedWork W2596550892 @default.
• W2108479875 hasRelatedWork W2615510955 @default.
• W2108479875 hasRelatedWork W2766845515 @default.
• W2108479875 hasRelatedWork W2900348376 @default.
• W2108479875 hasRelatedWork W2906583422 @default.
• W2108479875 hasRelatedWork W3159138021 @default.
• W2108479875 hasRelatedWork W4206060802 @default.
• W2108479875 hasRelatedWork W4251778690 @default.
• W2108479875 hasRelatedWork W1968744067 @default.
• W2108479875 hasVolume "23" @default.
• W2108479875 isParatext "false" @default.
• W2108479875 isRetracted "false" @default.
• W2108479875 magId "2108479875" @default.
• W2108479875 workType "article" @default.